Skip to content
AwardedBelgiumGoods

Spécialités pharmaceutiques à base de ECULIZUMAB et de RAVULIZUMAB

Published
Published 4 August 2025
Deadline
Closed 18 September 2025

Overview

Les nouveaux patients feront l’objet de ce marché public, les patients actuellement sous traitement ne doivent pas obligatoirement en changer. Le médecin gardera la possibilité d’utiliser la molécule la mieux adaptée aux besoins du patient.

Key details

Country
Belgium
Status
Awarded
Category
Goods
Procedure
Open
Published
4 August 2025
Deadline
Closed
Classification (CPV)
Pharmaceutical products

Award outcome

Awarded value
€2,520,000
Award date
6 November 2025
Contract period
— → 14 October 2029
Winner
  • AMGEN

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    12 November 2025

  2. Contract Notice

    4 August 2025

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Spécialités pharmaceutiques à base de ECULIZUMAB et de RAVULIZUMAB — won by AMGEN — Skim